Hims & Hers Health, Inc. (HIMS) closed at $29.72 in the latest trading session, marking a -0.3% move from the prior day. This move lagged the S&P 500's daily gain of 0.61%. Elsewhere, the Dow gained 0 ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atricure (ATRC – Research Report) and Hims ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

主要风险是， 如果FDA禁止复合GLP-1复合药物的新闻导致股价下跌，即使Hims & Hers Health准确地表示其个性化服务对业务的影响有限，市场也可能轻易忽视其强劲的核心业务， 直到在线健康平台证明GLP-1复合药物业务并非 驱动力 ...

Revman International is developing licensed collections for a pair of high-profile brands – one of which was the worst kept ...

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most ...

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

Sources tell Page Six Style that the couple hit up hotspot Kemo Sabe and left with some coordinating headwear.